Trials / Completed
CompletedNCT02475070
Vildagliptin Versus Dapagliflozin on Glucagon
Study of the Effect of Vildagliptin Versus Dapagliflozin on Glucagon Response to Mixed Meal in Metformin-treated Subjects With Type 2 Diabetes
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Lund University · Academic / Other
- Sex
- All
- Age
- 20 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the study is to assess if vildagliptin and dapagliflozin have dissociated effects on glucagon secretion after a mixed meal ingestion in metformin-treated subjects with type 2 diabetes and whether this is associated with effects on glucose homeostasis.
Detailed description
The aim of the study is to assess if vildagliptin and dapagliflozin have dissociated effects on glucagon secretion after a mixed meal ingestion in metformin-treated subjects with type 2 diabetes and whether this is associated with effects on glucose homeostasis. Subjects will therefore be treated with vildagliptin or dapagliflozin as add-on to metformin for two weeks followed by a meal test in which glucagon levels will be determined.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vildagliptin | Vildagliptin added at 50 mg twice daily for two weeks followed by four weeks washout and then dapagliflozin 10mg once daily for two weeks |
| DRUG | Dapagliflozin | Dapagliflozin added at 10 mg once daily for two weeks followed by four weeks washout and then vildagliptin 50 mg twice daily for two weeks |
Timeline
- Start date
- 2016-01-01
- Primary completion
- 2017-06-01
- Completion
- 2017-06-01
- First posted
- 2015-06-18
- Last updated
- 2019-05-02
- Results posted
- 2019-05-02
Locations
1 site across 1 country: Sweden
Source: ClinicalTrials.gov record NCT02475070. Inclusion in this directory is not an endorsement.